A facile ‰uorometric assay using D-kynurenine as a substrate was utilized for evaluating the inhibition of D-amino acid oxidase (DAAO), which is one of the products of a susceptibility gene for schizophrenia, by commercial antipsychotic drugs, namely, chlorpromazine (CPZ), carbamazepine, sulpiride, quetiapine, and imipramine. CPZ inhibited DAAO (65.8±13.2 mM, n＝3) as reported previously, and other drugs also inhibited DAAO activity. Among these, quetiapine had the smallest IC 50 value (19.5±2.60 mM, n＝3). The proposed assay can be useful for the evaluation or screening of DAAO-inhibitory drugs.
 e-mail: t-fukushima＠phar.toho-u.ac.jp (NMDA) receptor, 1) and plays an important role in regulating glutamatergic neurotransmission via the NMDA receptor. D-Serine is biosynthesized from Lserine by serine racemase (EC 5.1.1.16) 2, 3) in neuronal and/or glial cells, and is decomposed in glial cells by D-amino acid oxidase (DAAO) (EC 1.4.3.3), which is a ‰avin-adenine dinucleotide (FAD)-containing enzyme. 4 6) With regard to schizophrenia, one of the severe psychiatric diseases, the``glutamate hypothesis'' has recently been postulated; this hypothesis suggests that the etiology of schizophrenia may be associated with the hypofunction of the NMDA receptor. 7, 8) There have been reports stating that DAAO is one of the products of a susceptibility gene for schizophrenia 9) and that the activity of brain DAAO, which degrades D-serine, was found to be increased in the post-mortem brain tissue of patients with schizophrenia. 10) In addition, we previously reported that the serum D-serine concentration was signiˆcantly reduced in patients with schizophrenia. 11) In 1998, Tsai et al. reported that co-administration of D-serine with atypical antipsychotic drugs improved the symptoms of patients with schizophrenia. 12) Considering these reports together, DAAO inhibition by an exogenous drug could be eŠective for the treatment of schizophrenia. Therefore, screening or pharmacological studies on compounds that inhibit DAAO activity have come to be performed in the last decade. 13 16) In our previous study, we originally developed a ‰uorometric assay for DAAO inhibitors using Dkynurenine (D-KYN) as a substrate. 17) D-KYN is one of the D-amino acids, and is metabolized in vitro 17) or in vivo 18, 19) by DAAO to produce kynurenic acid (KYNA) 20, 21) that can emit ‰uorescence. After the enzymatic reaction of D-KYN with DAAO in the presence of a tested compound, a decrease degree in the ‰uorescence intensity emitted from KYNA indicates the ability of the tested compounds to inhibit DAAO. Compared with most other assay methods described previously, the proposed assay is facile, because it involves a one-step enzymatic reaction with DAAO. In the present study, some minor modiˆca-tions were made to further simplify the assay procedure.
Among psychotropic drugs, chlorpromazine (CPZ), which has a planar tricyclic structure, is mainly prescribed to patients with schizophrenia. Although CPZ is a typical antipsychotic drug that blocks the dopamine D 2 receptor, it is known that CPZ has the ability to inhibit DAAO. 22 24) It has been reported that the mechanism by which CPZ can in-hibit DAAO activity was through the replacement of the cofactor FAD with CPZ. 23, 24) Because most psychotropic drugs generally possess a planar tricyclic structure, other psychotropic drugs may have some DAAO-inhibitory activity. Therefore, we were interested in evaluating the inhibition of DAAO activity by other antipsychotic drugs prescribed to patients with psychiatric diseases. Thus, in the present study, we tested the ability of commercially available psychotropic drugs to inhibit DAAO activity using the modiˆed ‰uorometric assay.
MATERIALS AND METHODS

Materials
Pig kidney DAAO (pkDAAO) was obtained from Calzyme Laboratories Inc. (San Luis Obispo, CA, USA). D-KYN, KYNA, 3-methylpyrazole-5-carboxylic acid (MPC) 25) , 3-methylpyrazole-4-carboxylic acid, Trizmabase (min. 99.9％), bovine serum albumin (BSA), and chlorpromazine hydrochloride were obtained from Sigma (St. Louis, MO, USA). FAD was obtained from Nacalai Tesque (Kyoto, Japan). Zinc sulfate heptahydrate was obtained from Kanto Chemical Co. Ltd. (Tokyo, Japan). (±)-Sulpiride, carbamazepine, and imipramine hydrochloride were from Wako Pure Chemical Industries Co. Ltd. (Osaka, Japan). Quetiapine fumarate (Seroquel25 mg tablets) was obtained from Astellas Pharma Inc. (Tokyo, Japan). Water was puriˆed using a Milli-Q system (Millipore Co. Ltd., Bedford, MA, USA). Dimethylsulfoxide (DMSO) was obtained from Nacalai Chemicals Ltd. (Tokyo, Japan) and Tokyo Chemical Industries Co. Ltd.
(Tokyo, Japan), respectively. All other reagents were of reagent grade and were used without further puriˆ-cation. Benz[e]MTH-b-carboline 26) was synthesized in our laboratory in the Department of Synthetic Organic Chemistry.
DAAO Assay with D-KYN as a Substrate A DAAO assay was carried out according to the method in our previous paper 17) with a minor modiˆcation. We mixed 20 ml of 0.1 mg/ml DAAO in 0.4 M Tris buŠer solution (pH 8.3), 30 ml of 200 mM FAD solution, 20 ml of 2.0 mg/ml BSA in H 2 O, 390 ml of 0.4 M Tris buŠer solution (pH 8.3), and 20 ml of tested drugs or compounds dissolved in DMSO and incubated this at 37°C for 20 min. Next, 7.0 mM D-KYN (20 ml) were added and incubated at 37°C for 60 min. In the case of determination of K m , varying concentrations (1.4, 2.8, 4.2, 5.6, and 7.0 mM) of D-KYN (20 ml) were added in the presence or absence of the tested drugs, and incubated at 37°C for 60 min. The reaction mixture along with 1500 ml of 0.4 M Tris buŠer solution (pH 8.3) and 50 ml of 300 mM zinc sulfate dissolved in H 2 O. Theˆnal solution was subjected to vortex mixing, and the ‰uorescence of the solution was measured by a HITACHI F-7000 ‰uorescence spectrometer (Hitachi Co. Ltd., Tokyo, Japan). The ‰uorescence intensity of each solution was measured at an excitation wavelength of 250 nm and emission wavelength of 394 nm.
According to the following Eq. (1), the DF value was determined and used to calculate kinetic parameters (K m ) by using the Lineweaver-Burk plot:
DF＝F-F 0 (1) F and F 0 are ‰uorescence intensities of the sample and blank sample (a sample treated without D-KYN), respectively. For the inhibition curve, theˆnal concentrations of the test compounds were plotted on the X-axis, and the DF value in the absence of the inhibitor was set as 100％ on the Y-axis. The degree of inhibition for each test compound was expressed as a percentage according to the following Eq. (2):
Remaining activity of pkDAAO (％) ＝DF ′ /DF×100 (2) DF ′ is the DF value at each concentration of the inhibitor.
Calculation and Statistical Analysis IC 50 values of tested drugs were calculated by the following Eq.
) A and B are the higher and lower concentrations near 50％ inhibition, respectively, and C and D are the inhibition percentages at B and A, respectively. Statistical analysis of 2 groups was performed using the t test. A p value below 0.05 was considered signiˆcantly diŠerent.
RESULTS AND DISCUSSION
Modiˆcation of the Assay
In our previous study, we developed a screening assay method to identify inhibitors of DAAO using D-KYN as substrate. Using the enzymatic assay, production of a ‰uorescence compound, namely, KYNA, from D-KYN was previously conˆrmed by ‰uorescence spectrum, mass spectrometry, and column-switching HPLC. 17) In the present study, Tris buŠer (pH 8.3) and zinc sulfate were employed instead of borate buŠer (pH 8.3) and zinc acetate, respectively. These changes in the reagent produced no precipitation in the assay tubes when 300 mM zinc ion was added, thereby eliminating the need for a centrifugation step that removed the precipitate. Furthermore, no deproteinization procedure was performed, and the ‰uorescence originating from KYNA could be detected in the presence of proteins such as BSA and DAAO. Even though deproteinization was not performed, the obtained excitation and emission spectra were almost identical to those of KYNA, which exhibited 394 398 nm of optimum ‰uorescence with an excitation wavelength of 250 251 nm (Fig. 1) .
This result conˆrmed the production of KYNA from D-KYN by DAAO. Next, the modiˆed assay was tested by conˆrming whether DAAO was inhibited by a speciˆc inhibitor such as MPC. 25) As expected, it was observed that MPC inhibited DAAO activity ( Fig. 2(a) ) and produced an IC 50 value of 10.2± 2.15 mM (n＝3, Table 1 ). In contrast to MPC, there has been no information on the pharmacological actions of 3-methylpyrazole-4-carboxylic acid, which is the geometric isomer of MPC, as well as the inhibition of DAAO activity. As shown in Fig. 2(b) , 3-methylpyrazole-4-carboxylic acid showed very weak inhibition of DAAO activity. The proposed assay could discriminate the diŠerence in the extent of inhibition between MPC and 3-methylpyrazole-4-carboxylic acid, and thus, can be used for evaluating DAAO activity. In total, the number of steps in the procedure was reduced in the modiˆed assay, and therefore, this assay can be applied to high throughput screening in the future.
Inhibition of DAAO by Antipsychotic Drugs Figure 3 shows the inhibition curves of DAAO activity for representative antipsychotic drugs. In addition to CPZ (Fig. 3(a) ), the antipsychotic drugs quetiapine, sulpiride, carbamazepine, and imipramine (Fig. 3(b e) , respectively), which are currently prescribed to patients with schizophrenia, epilepsy, and depression, were tested. As shown in Fig. 3 , these antipsychotic drugs inhibited DAAO activity just as CPZ. Table 1 shows IC 50 values of antipsychotic drugs that inhibit DAAO activity, as determined by the proposed assay method. The present data on IC 50 of CPZ (ca. 66 mM) was considerably diŠerent from that of CPZ (ca. 1.9 mM) in the previous report. 17) The reason for the diŠerence is not clear, but in the previous method, the IC 50 value of CPZ might be imprecise, because some pretreatment steps for the determination were performed as described above. Among the antipsychotic drugs, quetiapine had the smallest IC 50 values (19.5±2.60 mM). With regard to the manner of inhibition, non-competitive inhibition between D-KYN (substrate) and quetiapine may occur, because no signiˆcant diŠerence in K m values in the presence (137±20.5 mM) or absence (164±14.0 mM) of 250 mM quetiapine was observed. With regard to CPZ, it was reported that DAAO activity was inhibited probably because of the replacement of FAD, which is a co-factor of DAAO, with CPZ that may occur during the enzymatic reaction. 22, 23) Similar to CPZ, quetiapine may be able to replace FAD and thus inhibit DAAO activity because it has a tricyclic structure like CPZ. The precise mechanism for the replacement or binding of these drugs to the FAD binding site is still unclear, but structural diŠerences between these drugs may produce the diŠerence in IC 50 observed in the present study.
In addition, benz[e]MTH-b-carboline 26) was originally a derivative of L-tryptophan, and in an in vitro screening assay, it was found to be an inhibitor of indole 2,3-dioxygenase (IDO), 27, 28) which was responsible for cleavage at the 2,3-position of the indole skeleton. It has recently been reported that IDO is in some manner associated with diseases such as Alzheimer's disease 27) and cancer, 28) but the preclinical and clinical trials of benz[e]MTH-b-carboline have not yet been performed.
As shown in Fig. 3(f) , benz[e]MTH-b-carboline was also found to inhibit DAAO activity. Benz[e] MTH-b-carboline possesses a planar polycyclic structure, and therefore, inhibited DAAO just like the antipsychotic drugs.
At present, much attention has been focused on the use of DAAO as a target drug for schizophrenia, and the creation of novel drugs that speciˆcally inhibit DAAO. 13 16,29) There have to date been few information on the DAAO inhibition activity of antipsychotic drugs tested in the present study. The present data suggest that the tested drugs can inhibit DAAO in the brain after they are administered. In order to ascertain this, analytical studies on the concentration of Dserine in biological specimens, including brain specimens, after treatment with these antipsychotic drugs should be performed. If these drugs have an ability to inhibit DAAO in vivo, DAAO-inhibitory activity will be an additional e‹cacy of these drugs in the pharmacotherapy for psychiatric diseases.
In conclusion, it was found that the proposed ‰uorescence assay in which D-KYN was used as a substrate was useful for evaluating the potential of drugs to inhibit DAAO activity, and will be useful for high throughput screening of DAAO inhibitors in the future.
